Bluejay Diagnostics (BJDX) Free Cash Flow (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of Free Cash Flow data on file, last reported at -$1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 35.82% year-over-year to -$1.6 million; the trailing twelve-month figure through Mar 2026 stood at -$6.7 million (up 4.66% YoY), and the FY2025 full-year result was -$6.2 million, up 23.38% from the prior year.
• Free Cash Flow grew to -$1.6 million in Q1 2026, from -$1.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$1.1 million in Q3 2023 to a low of -$3.2 million in Q4 2022.
• A 5-year average of -$2.0 million and a median of -$1.8 million in 2024 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow tumbled 413.63% in 2022 and jumped 49.3% in 2025, its largest moves.
• Tracing BJDX's Free Cash Flow over 5 years: stood at -$3.2 million in 2022, then grew by 12.76% to -$2.8 million in 2023, then jumped by 36.49% to -$1.8 million in 2024, then grew by 6.13% to -$1.7 million in 2025, then gained by 2.84% to -$1.6 million in 2026.
• Business Quant data shows BJDX's Free Cash Flow at -$1.6 million in Q1 2026, -$1.7 million in Q4 2025, and -$1.3 million in Q3 2025.